Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer

Abstract

Abstract: Objective To study e the therapeutic and adverse effects of ZD1839 in treating non-small-cell lung cancer (NSCLC). Methods The therapeutic and adverse effects of ZD1839 given orally were observed in 32 NSCLC cases after a treatment course more than 90 d. Results The rates of complete remission (CR), partial remission (PR), and stabilization (SD) were 0%, 18.75%, and 37.50% respectively, with a disease control rate of 56.25%. The adverse effects of this agent included acneiform rash, diarrhea, aminotransferase elevation, nausea and vomiting, occurring in 31.25%, 18.75%, 12.50% and 15.63% of the cases respectively. No interstitial lung disease was found. Conclusion ZD1839 is a new drug produeing acceptable disease control rate along with tolerable adverse effects in patients with lung cancer.

CLC Number:

R738.1

ZHANG Lin. Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer[J]. Journal of Southern Medical University, 2004, 24(09): 1061-1063.

References

[1] 李新旭,周同冲,赵健.非小细胞肺癌骨转移综合治疗临床分析[J].第一军医大学学报,2003,23(7):752-3.Li XX, Zhou TC, Zhao J. Clinical evaluation of combined-modality therapy for bone metastasis of non-small-cell lung cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(7): 752-3.
[2] 蔡红兵,代方国,闵清芬,等.中医药配合放疗治疗非小细胞肺癌的临床研究[J].第一军医大学学报,2002,22(12):1112-3.Cai HB, Dai FG, Min QF, et al. Clinical study of the effects of radiotherapy in combination with traditional Chinese medicine on nonsmall cell lung cancer[J]. J First Mil Med Univ/Di Yi JunYi Da Xue Xue Bao, 2002, 22(12): 1112-3.
[3] Sirotnak FM. Studies with ZD1839 in preclinical models[J]. Semin Oncol, 2003, 30 (1 Suppl 1): 12-20.
[4] Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors[J]. Semin Oncol, 2003, 30 (1 Suppl 1): 3-11.
[5] Herbst RS. Dose-comparative monotherapytrials of ZD1839 inpreviously treated non-small cell lung cancer patients[J]. Semin Oncol,2003, 30(1 Suppl 1): 30-8.
[6] Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial ofgefitinib for previously treated patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2003, 21(12):2237-46.
[7] Schiller JH. New directions for ZD1839 in the treatment of solid tumors[J]. Semin Oncol, 2003, 30(1 Suppl 1): 49-55.
[8] Baselga J, Rischin D, Ranson M. Phase Ⅰ safety, pharmacokinetic,and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol, 2002, 20(21): 4292-302.
[9] Lorusso PM. Phase Ⅰ studies of ZD1839 in patients with common solid tumors[J]. Semin Oncol, 2003, 30 (Suppl 1): 21-9.